HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Raises Price Target to $77

Benzinga · 10/11 10:28
HC Wainwright & Co. analyst Joseph Pantginis maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $40 to $77.